James E Swain1, Lawrence Scahill2, Paul J Lombroso2, Robert A King2, James F Leckman2. 1. Drs. Swain, Scahill, Lombroso, King, and Leckman are with the Child Study Center of Yale University, New Haven, CT; and Dr. Scahill is also with the School of Nursing at Yale University.. Electronic address: james.leckman@yale.edu. 2. Drs. Swain, Scahill, Lombroso, King, and Leckman are with the Child Study Center of Yale University, New Haven, CT; and Dr. Scahill is also with the School of Nursing at Yale University.
Abstract
OBJECTIVE: This is a review of progress made in the understanding of Tourette syndrome (TS) during the past decade including models of pathogenesis, state-of-the-art assessment techniques, and treatment. METHOD: Computerized literature searches were conducted under the key words "Tourette syndrome," "Tourette disorder," and "tics." Only references from 1996-2006 were included. RESULTS: Studies have documented the natural history of TS and the finding that tics usually improve by the end of the second decade of life. It has also become clear that TS frequently co-occurs with attention-deficit/hyperactivity disorder), obsessive-compulsive disorder, and a range of other mood and anxiety disorders. These comorbid conditions are often the major source of impairment for the affected child. Advances have also been made in understanding the underlying neurobiology of TS using in vivo neuroimaging and neurophysiology techniques. Progress on the genetic front has been less rapid. Proper diagnosis and education (involving the affected child and his or her parents, teachers, and peers) are essential prerequisites to the successful management of children with TS. When necessary, modestly effective antitic medications are available, although intervening to treat the comorbid attention-deficit/hyperactivity disorder and/or obsessive-compulsive disorder is usually the place to start. CONCLUSIONS: Prospective longitudinal studies and randomized clinical trials have led to the refinement of several models of pathogenesis and advanced our evidence base regarding treatment options. However, fully explanatory models are needed that would allow for more accurate prognosis and the development of targeted and efficacious treatments.
OBJECTIVE: This is a review of progress made in the understanding of Tourette syndrome (TS) during the past decade including models of pathogenesis, state-of-the-art assessment techniques, and treatment. METHOD: Computerized literature searches were conducted under the key words "Tourette syndrome," "Tourette disorder," and "tics." Only references from 1996-2006 were included. RESULTS: Studies have documented the natural history of TS and the finding that tics usually improve by the end of the second decade of life. It has also become clear that TS frequently co-occurs with attention-deficit/hyperactivity disorder), obsessive-compulsive disorder, and a range of other mood and anxiety disorders. These comorbid conditions are often the major source of impairment for the affected child. Advances have also been made in understanding the underlying neurobiology of TS using in vivo neuroimaging and neurophysiology techniques. Progress on the genetic front has been less rapid. Proper diagnosis and education (involving the affected child and his or her parents, teachers, and peers) are essential prerequisites to the successful management of children with TS. When necessary, modestly effective antitic medications are available, although intervening to treat the comorbid attention-deficit/hyperactivity disorder and/or obsessive-compulsive disorder is usually the place to start. CONCLUSIONS: Prospective longitudinal studies and randomized clinical trials have led to the refinement of several models of pathogenesis and advanced our evidence base regarding treatment options. However, fully explanatory models are needed that would allow for more accurate prognosis and the development of targeted and efficacious treatments.
Authors: Yingfang Tian; Isaac H Liao; Xinhua Zhan; Joan R Gunther; Bradley P Ander; Dazhi Liu; Lisa Lit; Glen C Jickling; Blythe A Corbett; Netty G P Bos-Veneman; Pieter J Hoekstra; Frank R Sharp Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2010-11-17 Impact factor: 3.568
Authors: Hannah Weisman; Imraan A Qureshi; James F Leckman; Lawrence Scahill; Michael H Bloch Journal: Neurosci Biobehav Rev Date: 2012-10-23 Impact factor: 8.989
Authors: G Nestadt; C Z Di; M A Riddle; M A Grados; B D Greenberg; A J Fyer; J T McCracken; S L Rauch; D L Murphy; S A Rasmussen; B Cullen; A Pinto; J A Knowles; J Piacentini; D L Pauls; O J Bienvenu; Y Wang; K Y Liang; J F Samuels; K Bandeen Roche Journal: Psychol Med Date: 2008-12-02 Impact factor: 7.723
Authors: Rafael Garcia-Lopez; Emilio Perea-Milla; Cesar Ruiz Garcia; Francisco Rivas-Ruiz; Julio Romero-Gonzalez; Jose L Moreno; Vicente Faus; Guadalupe del Castillo Aguas; Juan C Ramos Diaz Journal: Trials Date: 2009-03-10 Impact factor: 2.279